Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Many European countries are not ready to stop viral hepatitis

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal - an institution supported by the "la Caixa" Foundation - and led by the European Liver Patient's Association.

Published
19 April 2018
From
Eurekalert Medicine & Health
Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe

“Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C

Published
19 April 2018
By
Michael Carter
Curing hepatitis C reduces deaths and liver disease

Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show.

Published
18 April 2018
By
Keith Alcorn
Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe

There has been a steep fall in the number of hepatitis C virus (HCV)-related liver transplants since the introduction of direct-acting antivirals (DAAs), according to

Published
16 April 2018
By
Michael Carter
Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy

An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons

Published
13 April 2018
By
Keith Alcorn
Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

A longitudinal study involving more than 1,000 individuals reports promising role for linkage to care specialists in expanding access to hepatitis C treatment for people who inject drugs. Almost 50% of patients referred to a medical practitioner made it to their first appointment and that 60% of those seen were initiated on treatment.

Published
13 April 2018
From
Eurekalert Inf Dis
New affordable hepatitis C combination shows 97% cure rate

The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and

Published
12 April 2018
By
Keith Alcorn
How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Published
10 April 2018
From
Poz
8-week course of Zepatier cures acute HCV in people with HIV

An 8-week course of grazoprevir/elbasvir (Zepatier) produced sustained virological response in most HIV-positive gay men with recent hepatitis C virus (HCV) genotype 1 or 4 infection, according

Published
04 April 2018
By
Liz Highleyman
Newly Discovered HCV Subtype is Resistant to Antiviral Treatment

A newly discovered hepatitis C virus (HCV) genotype 1 subtype harbors multiple resistance-associated mutations that combine to block therapeutic effect of NS5A inhibitor direct-acting antivirals (DAAs).

Published
21 March 2018
From
MD Magazine
← First12345...98Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.